HomeAI · summaries
Storia in 3 fonti
Blackstone scommette su Apogee Therapeutics fino a 1,3 miliardi
Il finanziamento è per lo sviluppo di zumilokibart, potenziale rivale di Dupixent, farmaco sviluppato da Regeneron Pharmaceuticals e Sanofi
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
benzinga.com
Apogee Stock Slides After Blackstone Financing Deal And Positive Drug Data - Apogee Therapeutics (NASDAQ:
Apogee shares fell after announcing a $1.3 billion Blackstone financing deal alongside positive Phase 2 eczema drug results.
- ·
endpoints.news
Apogee lands Blackstone $800M royalty deal to move Dupixent rival toward Phase 3
Apogee Therapeutics secures up to $800 million royalty deal with Blackstone Life Sciences to fund Phase 3 trials of eczema drug zumilokibart.
